KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on Certara (CERT) to $8 from $10 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup is largely positive, with beats likely across the group. That said, KeyBanc thinks most companies will reiterate their full-year guidance given the uncertain macro. Thematically, it believes healthcare systems are continuing to see good utilization, supporting capex/ software spend, and Pharma digital advertising environment remains choppy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara Announces Upcoming Board and Audit Committee Change
- Certara price target lowered to $10 from $15 at UBS
- Certara: Capitalizing on Growing Biosimulation Adoption Despite Near-Term Software Headwinds
- Certara downgraded to Equal Weight from Overweight at Barclays
- Certara announces Simcyp Simulator predictions accepted by U.S. FDA